Retina/Vitreous News

Adherence to intravitreal anti-VEGF injections may be challenging for some patients with neovascular age-related macular degeneration, putting them at risk for poor vision outcomes, according to research published in Ophthalmology Science.

A study presented at Angiogenesis, Exudation, and Degeneration 2024 provided insights on how geographic atrophy precursors present across multiple imaging modalities.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, presents 1-year real-world findings for faricimab as a treatment for neovascular age-related macular degeneration.

Researchers have identified biomarkers that predict age-related macular degeneration progression as well as biomarkers associated with progression to geographic atrophy and neovascularization, according to a review published in Ophthalmology Retina.

Beacon Therapeutics announced the presentation of interim safety and efficacy results from the phase 2 SKYLINE trial evaluating AGTC-501 gene therapy for X-linked retinitis pigmentosa.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, overviews phase 2 efficacy and safety data for 4D-150 for the treatment of neovascular age-related macular degeneration.

Vision-related quality of life declined with the presence and severity of diabetic retinopathy, highlighting the importance of interventions to reduce disease progression, according to a study published in JAMA Ophthalmology.

Oral APX3330 showed clinically meaningful response compared with placebo in slowing progression of diabetic retinopathy in the phase 2 ZETA-1 trial.

Hearing loss occurred more frequently among adults who received teprotumumab for the treatment of thyroid eye disease if they had impaired hearing at the start of therapy, according to a research letter published in Thyroid.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Rishi P. Singh, MD, overviews post hoc analyses supporting angiopoietin-2 inhibition for treating retinal diseases.